Therapeutics approved for clinical use have varying degrees of side effects and none can eradicate the HIV-1

Therapeutics approved for clinical use have varying degrees of side effects and none can eradicate the HIV-1. HIV-1 continues to be a major public health problem, and SBE13 new safer and more effective therapies are needed. Therapeutics approved for clinical use have varying degrees of side effects and none can eradicate the HIV-1. Protein therapeutics are typically cell target-specific and relatively safe1. Currently, antibody therapeutics are dominant protein therapeutics with more than 50 monoclonal antibodies (mAbs) approved for clinical use2. However, there are no mAbs approved for therapy against any viral diseases. The humanized mAb Synagis is the only one approved by the FDA against a viral disease, however, it is only for prevention and not for therapy3. The identification of novel potent broadly neutralizing antibodies (bnAbs) against HIV-1 during the SBE13 last several years gave new hopes to the old idea to use antibodies as anti-HIV-1 therapeutics. Attempts to use bnAbs alone or in combination or as components of chimeric antigen receptors (CARs), bispecific T cell engagers (BiTEs) and other bispecific proteins resulted in promising results both and test (panel b). A two-tailed value?EIF4G1 able to kill cells infected with all isolates, and escape of resistant virus may be difficult although future experiments are needed to prove this statement. Furthermore, one can envision that mD1.22 in the BiKEs could also act as an HIV-1 entry inhibitor independent of its effect on NK cells, which could lead to synergistic effects. Another unique feature of our BiKEs is that they are based on fully human molecules. The CD16A.